Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

This study is testing serplulimab, an immunotherapy drug, given after standard chemoradiation therapy in patients with limited-stage small cell lung cancer (SCLC) — a type of lung cancer that is confined to one side of the chest — to see if it can prevent the cancer from coming back. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with limited-stage small cell lung cancer (confirmed by biopsy or cell sample) - You are in good overall health (ECOG performance status 0-1) - You have not had any prior treatment for this cancer - Your organ function is adequate **You may NOT be eligible if...** - Your cancer has spread to both sides of the chest or beyond - You have had prior lung cancer treatment - You have significant autoimmune disease or major organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.